Esperion Sale at $3.16 Per Share Includes $100M CVRs, Faces Rights Probe
Esperion Therapeutics agreed to a $1.1B sale to Archimed at $3.16 per share plus CVRs up to $100M tied to bempedoic acid and bumetanide milestones, a 58% premium over April 30 price. Halper Sadeh LLC is probing whether the deal limits bids and grants insiders benefits not available to shareholders.
1. Acquisition Deal Terms
Esperion Therapeutics has agreed to be acquired by funds managed by Archimed for approximately $1.1 billion, receiving $3.16 per share in cash. The deal includes contingent value rights worth up to $100 million based on future sales milestones for bempedoic acid and bumetanide products, representing a 58% premium to the April 30 closing price.
2. Shareholder Rights Investigation
Investor rights firm Halper Sadeh LLC is investigating whether the transaction contains provisions that restrict competing offers and confer disproportionate benefits on insiders. The firm may seek increased consideration or additional disclosures on behalf of Esperion shareholders, pursuing relief on a contingent fee basis without upfront costs.